Literature DB >> 1785004

Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group.

A Sell, A Jakobsen, B Nerstrøm, B L Sørensen, K Steven, H Barlebo.   

Abstract

From 1983 to 1986 183 patients with transitiocellular carcinoma of the urinary bladder, category T2-T4a, entered a randomized study. The patients were allocated to receive either preoperative irradiation (40 Gy) followed by cystectomy or radical irradiation (60 Gy) followed by salvage cystectomy in cases of residual tumor. The two randomization groups were comparable in regard to sex, age, T-categories, tumor size, histological grade and concomitant dysplasia. The two randomization groups included 88 and 95 patients respectively. The treatment plan was followed by 66 patients (75%) in the planned cystectomy group and by 88 (92%) in the radical radiotherapy group of which 27 (28%) were treated with salvage cystectomy. The results showed a trend to a higher survival rate following the combined treatment with preoperative irradiation and cystectomy compared to radical irradiation followed by salvage cystectomy in case of residual tumor, but a statistical significant difference could not be demonstrated. The lack of difference also applied according to the actually given treatment. There was no difference in surgical complications between planned and salvage cystectomy and there were no postoperative deaths among the cystectomized patients. The type of late complications was different in the two treatment groups, but there were no major differences in the number of complications except for the fact that all male patients experienced erective impotence after cystectomy. The T-category, response to radiotherapy and frequency of lymph node metastases were found to be of prognostic importance.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1785004

Source DB:  PubMed          Journal:  Scand J Urol Nephrol Suppl        ISSN: 0300-8886


  10 in total

1.  Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy.

Authors:  Kevin R Kozak; Maryam Hamidi; Matthew Manning; John S Moody
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-06       Impact factor: 7.038

2.  Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy.

Authors:  Arjun Balar; Dean F Bajorin; Matthew I Milowsky
Journal:  Ther Adv Urol       Date:  2011-06

Review 3.  Bladder cancer: a review of diagnosis and management.

Authors:  M C Metts; J C Metts; S J Milito; C R Thomas
Journal:  J Natl Med Assoc       Date:  2000-06       Impact factor: 1.798

Review 4.  Current Concepts in the Management of Muscle Invasive Bladder Cancer.

Authors:  Suprita R Krishna; Badrinath R Konety
Journal:  Indian J Surg Oncol       Date:  2016-12-15

Review 5.  Bladder-sparing approaches to invasive disease.

Authors:  Jason A Efstathiou; Anthony L Zietman; Donald S Kaufman; Niall M Heney; John J Coen; William U Shipley
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

Review 6.  Contemporary management of muscle-invasive bladder cancer.

Authors:  Marc A Dall'Era; Liang Cheng; Chong-Xian Pan
Journal:  Expert Rev Anticancer Ther       Date:  2012-07       Impact factor: 4.512

7.  Effective bladder preservation strategy with low-dose radiation therapy and concurrent intraarterial chemotherapy for muscle-invasive bladder cancer.

Authors:  Hitoshi Ikushima; Seiji Iwamoto; Kyohsuke Osaki; Shunsuke Furutani; Kyoh Yamashita; Takashi Kawanaka; Akiko Kubo; Yoshihiro Takegawa; Takaharu Kudoh; Hiroomi Kanayama; Hiromu Nishitani
Journal:  Radiat Med       Date:  2008-04

Review 8.  SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.

Authors:  Jeffrey J Leow; Jens Bedke; Karim Chamie; Justin W Collins; Siamak Daneshmand; Petros Grivas; Axel Heidenreich; Edward M Messing; Trevor J Royce; Alexander I Sankin; Mark P Schoenberg; William U Shipley; Arnauld Villers; Jason A Efstathiou; Joaquim Bellmunt; Arnulf Stenzl
Journal:  World J Urol       Date:  2019-01-25       Impact factor: 4.226

9.  A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice.

Authors:  Ben-Max de Ruiter; Maaike W van de Kamp; Jonah P Z van Steenbergen; Martine Franckena; Joost L Boormans; Jeantine M de Feijter; Adriaan D Bins; Maarten C C M Hulshof; Theo M de Reijke; Eva Schaake; Jorg R Oddens
Journal:  Eur Urol Open Sci       Date:  2022-03-16

10.  Conservative treatment of invasive bladder cancer.

Authors:  N J Rene; F B Cury; L Souhami
Journal:  Curr Oncol       Date:  2009-08       Impact factor: 3.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.